- Home
- FMAO vs ETON Comparison
FMAO vs ETON Comparison
Compare FMAO & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- ETON
- Stock Information
- Founded
- FMAO 1897
- ETON 2017
- Country
- FMAO United States
- ETON United States
- Employees
- FMAO N/A
- ETON N/A
- Industry
- FMAO Savings Institutions
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- FMAO Finance
- ETON Health Care
- Exchange
- FMAO Nasdaq
- ETON Nasdaq
- Market Cap
- FMAO 359.3M
- ETON 388.3M
- IPO Year
- FMAO N/A
- ETON 2018
- Fundamental
- Price
- FMAO $26.52
- ETON $18.46
- Analyst Decision
- FMAO
- ETON Strong Buy
- Analyst Count
- FMAO 0
- ETON 3
- Target Price
- FMAO N/A
- ETON $29.67
- AVG Volume (30 Days)
- FMAO 16.9K
- ETON 205.9K
- Earning Date
- FMAO 10-29-2025
- ETON 11-11-2025
- Dividend Yield
- FMAO 3.36%
- ETON N/A
- EPS Growth
- FMAO 38.39
- ETON N/A
- EPS
- FMAO 2.16
- ETON N/A
- Revenue
- FMAO $108,632,000.00
- ETON $58,181,000.00
- Revenue This Year
- FMAO $3.38
- ETON $105.25
- Revenue Next Year
- FMAO $6.39
- ETON $40.84
- P/E Ratio
- FMAO $12.20
- ETON N/A
- Revenue Growth
- FMAO 13.86
- ETON 85.40
- 52 Week Low
- FMAO $20.88
- ETON $5.35
- 52 Week High
- FMAO $34.15
- ETON $21.48
- Technical
- Relative Strength Index (RSI)
- FMAO 55.54
- ETON 67.44
- Support Level
- FMAO $25.08
- ETON $17.24
- Resistance Level
- FMAO $26.50
- ETON $18.52
- Average True Range (ATR)
- FMAO 0.81
- ETON 0.70
- MACD
- FMAO -0.04
- ETON -0.02
- Stochastic Oscillator
- FMAO 69.01
- ETON 93.16
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company based in Ohio. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.